The GRM7 antibody is a research tool designed to detect and study the metabotropic glutamate receptor 7 (mGluR7 or GRM7), a G protein-coupled receptor (GPCR) belonging to Group III of the metabotropic glutamate receptor family. GRM7 is primarily expressed in the central nervous system, where it modulates synaptic transmission and plasticity by inhibiting cAMP production and activating MAPK signaling pathways. It plays a critical role in regulating neurotransmitter release, neuronal excitability, and synaptic connectivity, making it a focus in neuropsychiatric and neurological disorder research, including anxiety, epilepsy, and schizophrenia.
GRM7 antibodies are typically polyclonal or monoclonal reagents developed to target specific epitopes on the receptor, enabling applications like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help investigate GRM7's expression patterns, cellular localization, and interactions in both healthy and disease contexts. Studies using GRM7 antibodies have contributed to understanding its involvement in synaptic dysfunction, neurodevelopmental disorders, and potential therapeutic targeting. Recent research also explores GRM7's role in non-neuronal tissues, such as cancer, where aberrant receptor activity may influence tumor progression. Validation of GRM7 antibodies ensures specificity and reliability, critical for advancing mechanistic insights into its physiological and pathological functions.